cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Proqr Therapeutics Nv
9 own
17 watching
Current Price
$1.86
$-0.03
(-1.59%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
125.37M
52-Week High
52-Week High
3.29000
52-Week Low
52-Week Low
1.11000
Average Volume
Average Volume
0.09M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization125.37M
icon52-Week High3.29000
icon52-Week Low1.11000
iconAverage Volume0.09M
iconDividend Yield--
iconP/E Ratio--
What does the Proqr Therapeutics Nv do?
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber s congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as ProQR Therapeutics VIII B.V. for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Read More
News & Events about Proqr Therapeutics Nv.
PR Newswire
1 year ago
Thinking about buying stock in Thermogenesis Holdings, ProQR Therapeutics, Grom Social, ORIC Pharmaceuticals, or Acasti Pharma? Thinking about buying stock in Thermogenesis Holdings, ProQR Therapeutics, Grom Social, ORIC Pharmaceuticals, or Acasti Pharma? PR Newswire NEW YORK, Dec. 22, 2022 NEW...
Globe Newswire
1 year ago
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and webcast to discuss the...
PR Newswire
1 year ago
Lilly and ProQR to Expand RNA Editing Collaboration Lilly and ProQR to Expand RNA Editing Collaboration PR Newswire INDIANAPOLIS and LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 22, 2022 New agreement supports the discovery and development of additional assets directed toward high conviction...
Globe Newswire
1 year ago
New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQRs Axiomer technologyINDIANAPOLIS; LEIDEN, Netherlands; and CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V...
Ticker Report
1 year ago
StockNews.com downgraded shares of ProQR Therapeutics (NASDAQ:PRQR Get Rating) from a hold rating to a sell rating in a research report released on Friday morning. Other equities analysts have also issued reports about the stock. Cantor Fitzgerald lowered shares of ProQR Therapeutics from an...
Frequently Asked Questions
Frequently Asked Questions
What is Proqr Therapeutics Nv share price today?
plus_minus_icon
Can Indians buy Proqr Therapeutics Nv shares?
plus_minus_icon
How can I buy Proqr Therapeutics Nv shares from India?
plus_minus_icon
Can Fractional shares of Proqr Therapeutics Nv be purchased?
plus_minus_icon
What are the documents required to start investing in Proqr Therapeutics Nv stocks?
plus_minus_icon
What is today’s traded volume of Proqr Therapeutics Nv?
plus_minus_icon
What is today’s market capitalisation of Proqr Therapeutics Nv?
plus_minus_icon
What is the 52-Week High and Low Range of Proqr Therapeutics Nv?
plus_minus_icon
What percentage is Proqr Therapeutics Nv down from its 52-Week High?
plus_minus_icon
What percentage is Proqr Therapeutics Nv up from its 52-Week Low?
plus_minus_icon
Current Price
$1.86
$-0.03
(-1.59%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$93.19
$-0.51 (-0.54 %)
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$1.09
$-0.02 (-1.80 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$4.55
$0.04 (0.89 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$1.40
$0.01 (0.72 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$93.19
$-0.51 (-0.54 %)
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$1.09
$-0.02 (-1.80 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$4.55
$0.04 (0.89 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$1.40
$0.01 (0.72 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00